- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04540601
Antiresorptive Drug Continuation Compared With Drug Holiday in Cancer Patients Needing Tooth Extraction (DrugHoliday)
Antiresorptive Drug Continuation Compared With Drug Holiday in Cancer Patients Needing Tooth Extraction - A Randomized Clinical Trial
The aim of this trial is to evaluate high-dose antiresorptive drug holiday related to tooth extraction with primary mucosal closure (surgical extraction) including how a drug holiday affects the health related quality of life.
Research question: Does a drug holiday have any influence on health related quality of life or the incidence of developing osteonecrosis of the jaw after surgical tooth extraction? The investigators hypothesize that a drug holiday 1 month before to 3 months after surgical tooth extraction in cancer patients do not influence the development of osteonecrosis of the jaw and may even affect the health related quality of life negatively.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Osteonecrosis of the jaw is a known adverse reaction to antiresorptive medication, including bisphosphonate and denosumab. The globally accepted term is Medication-Related Osteonecrosis of the Jaws (MRONJ). Since 2003 there has been a worldwide focus at medication-related osteonecrosis, even though there still exist several of unanswered questions - one of them is the effect of a drug holiday in relation to tooth extraction. A drug holiday is a temporary discontinuation of a drug and has been suggested among risk reduction strategies in the literature. It is still unknown whether a drug holiday plays a significant role in relation to tooth extraction for the development of osteonecrosis. The investigators want to investigate the importance of an antiresorptive drug holiday (bisphosphonate, denosumab) in relation to tooth extraction.
The aim of this trial is therefore to clarify the meaning of high-dose antiresorptive drug holiday related to tooth extraction with primary mucosal closure in cancer patients and reveal how a drug holiday affects the health related quality of life. A continuation of the patients' antiresorptive treatment can possibly lead to increased risk of osteonecrosis of the jaw, but with the operation procedure with primary closure it is unlikely. It is beneficial for the cancer patients to continue the high dose antiresorptive therapy because a drug holiday is a stop in their anti-cancer treatment with risk of increased pain as well as unwanted skeletal events to occur, and potentially progress of metastases to follow.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Copenhagen Ø
-
Copenhagen, Copenhagen Ø, Denmark, 2100
- Copenhagen University Hospital
-
-
Nørrebro
-
Copenhagen, Nørrebro, Denmark, 2200
- University of Copenhagen, Department of Odontology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients eligible for the trial must comply with all of the following at randomization:
- Patients aged 18 years or older.
- Patients with malignant disease (breast or prostate cancer, multiple myeloma) and metastases to the skeleton.
- Patients present high dose/intravenous antiresorptive therapy for at least 1 month.
- Patients who need tooth extraction. Indications for extraction include root fracture, endodontic failure, severe periodontal disease, non-restorable caries and teeth with a poor prognosis or at high risk of infection, complications.
Patients who have an ECOG (Eastern Cooperative Oncology Group) score < 2 (30). Definition of ECOG 0. Fully active, able to carry on all pre-disease performance without restriction.
- Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature e.g., light house work, office work.
- Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of walking hours.
- Capable of only limited selfcare, confined to bed or chair more than 50% of walking hours.
- Completely disabled. Cannot carry on selfcare. Totally confined to bed or chair.
- Signed informed content.
Exclusion Criteria:
- Patients must not have received radiation therapy to the jaws.
- Patients must not have exposed bone, or signs of non-exposed bone.
- Patients previous diagnosed with ONJ.
- Patients who are unable to cooperate or too ill to complete the experiment.
- Lack of signed informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cancer patients, randomized A
Patients in high-dose antiresorptives with bone metastases
|
We want to investigate the importance of an antiresorptive drug holiday (bisphosphonate, denosumab) in relation to tooth extraction. The experimental intervention in this trial is drug continuation starting before tooth extraction with primary closure. We simply ask the participating cancer patients to continue their high dose antiresorptive treatment for 4 months (intervention-period: 1 month pre-operative, 3 months post-operative) instead of taking a drug holiday. |
No Intervention: Cancer patients, randomized B
Drug Holiday as standard operation procedure
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development of osteonecrosis of the jaw (ONJ) or incomplete healing at 3 months follow-up
Time Frame: 3 months follow-up
|
The outcome assessor has 3 options for registration related to ONJ occurrence:
|
3 months follow-up
|
EQ-5D-5L: Change in patients health related quality of life from allocation/enrollment
Time Frame: The patient will be asked to fulfill the EQ-5D-5L at allocation/enrollment and again at 1, 3 and 6 months follow-up.
|
The patients are given the EQ-5D-5L questionnaire.
The 5-level EQ-5D version (EQ-%D-5L) was introduced by the EuroQol Group in 2009 and consists of two pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Each dimension has 5 levels: no problems, slight problems, moderate problems, serve problems and extreme problems.
The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
The Danish dataset (SPSS syntax crosswalk values EQ-5D-5L Denmark) will be used to analyze patients´ responses.
|
The patient will be asked to fulfill the EQ-5D-5L at allocation/enrollment and again at 1, 3 and 6 months follow-up.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain from the jaw
Time Frame: This is asked prior to tooth extraction (time 0), at suture removal (time 10-14 days), at 1-month follow-up and at 3 and 6 months follow-up and is registered in the datasheet.
|
Pain from the jaw is registered by a Visual Analogue Scale (VAS).
The investigator will give the patient a paper with a VAS, see attached appendix 3, and ask following question: "On a scale from 0 to 10, where 0 is no pain and 10 is the worst thinkable pain, mark at the scale how much pain you feel from your jaw at tooth operation site".
|
This is asked prior to tooth extraction (time 0), at suture removal (time 10-14 days), at 1-month follow-up and at 3 and 6 months follow-up and is registered in the datasheet.
|
Incidence of unwanted skeletal events
Time Frame: Incidence (number of) unwanted skeletal events during the period and is registered at 3 and 6 months follow-up.
|
The patient is giving a simple questionnaire, where they have to answer yes or no to following question: "Have you visited your own doctor or been hospitalized because of fractures or other skeletal complications during this trial period - yes or no.
If yes, please write why."
See attached appendix 4: Skeletal-related event questionnaire
|
Incidence (number of) unwanted skeletal events during the period and is registered at 3 and 6 months follow-up.
|
Progression of cancer disease
Time Frame: The patient will be weighted at baseline, time of tooth removal, 1 month follow-up, 3 and 6 months follow-up visit.
|
The tumor-evaluation will be done by the oncologic doctor in due to their departments routine.
|
The patient will be weighted at baseline, time of tooth removal, 1 month follow-up, 3 and 6 months follow-up visit.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-18007990
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteonecrosis Due to Drugs, Jaw
-
Centre Hospitalier Sud FrancilienTerminatedOsteonecrosis Due to Drugs, JawFrance
-
Shiraz University of Medical SciencesShahid Beheshti University of Medical SciencesCompletedOsteonecrosis Due to Drugs, Jaw
-
Centre Hospitalier Universitaire de BesanconRecruitingOsteonecrosis Due to Drugs, JawFrance
-
University of Roma La SapienzaUniversidade da Coruña; NYU College of DentistryUnknownOsteonecrosis Due to Drugs, Jaw
-
The University of The West IndiesRecruiting
-
Northwell HealthWithdrawnPlatelet Dysfunction Due to Drugs
-
The University of The West IndiesCompletedPlatelet Dysfunction Due to DrugsTrinidad and Tobago
-
The University of The West IndiesCompletedPlatelet Dysfunction Due to DrugsTrinidad and Tobago
-
University of Santiago de CompostelaCompletedHead and Neck Cancer | Oral Cancer | Oral Mucositis | Osteoradionecrosis | Hyposalivation | Osteonecrosis Due to Drugs, Jaw | Osteonecroses, BisphosphonateSpain
-
Hamilton Health Sciences CorporationUnknownAspirin | Platelet Dysfunction Due to Drugs | Ticagrelor | TransfusionCanada
Clinical Trials on Continuation of antiresorptives in relation to tooth extraction (surgical tooth removal)
-
Minia UniversityActive, not recruitingDental Implant Failure NosEgypt
-
University of Novi SadActive, not recruitingDental Caries | Inferior Alveolar Nerve | Anesthesia, Dental | Primary TeethSerbia
-
British University In EgyptRecruitingPost Operative Pain | Root Canal Sealers | Sillicon Based Sealers | Resin Based SealersEgypt
-
University Clinical Centre of KosovaUniversity of Ljubljana, Faculty of MedicineUnknownType 2 Diabetes Mellitus | PeriodontitisKosovo